Prevalence and features of allergic bronchopulmonary aspergillosis, United States, 2016–2022
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0317054 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Kaitlin Benedict und 3 weiteren Autor:innen. Beteiligte Einrichtung: Mycotic Diseases Branch, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases…. Hauptthemen laut MEDLINE: Aspergillosis, Allergic Bronchopulmonary. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0).
Abstract (Originalsprache)
The epidemiology of allergic bronchopulmonary aspergillosis (ABPA) in the United States is not well-described. To estimate national ABPA prevalence among patients with asthma or cystic fibrosis, characterize ABPA testing practices, and describe ABPA clinical features, treatment, and 6-month outcomes. We used the 2016–2022 Merative™ MarketScan® Commercial/Medicare and Multi-State Medicaid Databases to identify cohorts of patients with 1) asthma, 2) cystic fibrosis (CF), and 3) ABPA. We calculated ABPA prevalence per 10,000 patients with asthma or CF, assessed diagnostic testing for ABPA among patients with severe asthma, and described features of patients with ABPA using diagnosis and procedure codes. The overall ABPA prevalence among patients with asthma was 2.8/10,000 (Commercial/Medicare) and 1.0/10,000 (Medicaid). ABPA prevalence increased with asthma severity (Commercial/Medicare: mild 1.3, moderate 9.3, severe 70.6, Medicaid: mild 0.3, moderate 2.4, severe 32.4). Among patients with CF, ABPA prevalence was 183.7/10,000 (Commercial/Medicare) and 134.6/10,000 (Medicaid). Among patients with severe asthma, 10.3% (Commercial/Medicare) and 7.4% (Medicaid) received total immunoglobulin E testing, which is recommended for ABPA diagnosis. Among all patients with ABPA (Commercial/Medicare: n = 1,564, Medicaid: n = 410), ABPA treatments included inhaled corticosteroids (>70%), systemic corticosteroids (>62%), and antifungals (>18%). Patients with ABPA and Medicaid were more likely to experience hospitalization (45.1% vs. 22.5% of patients with Commercial/Medicare insurance) and respiratory failure (18.5% vs. 10.9%). This analysis provides initial estimates of national ABPA prevalence. Further studies could identify potential barriers to ABPA testing and investigate potential factors affecting payer-related differences in ABPA burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Mycotic Diseases Branch, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United…
- Asthma and Air Quality Branch, Division of Environmental Health Science and Practice, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
ORCID-Profile: Kaitlin Benedict
Zitieren
APA
Benedict, K., Gold, J. A. W., Toda, M., & Hsu, J. (2025). Prevalence and features of allergic bronchopulmonary aspergillosis, United States, 2016–2022. PLOS ONE. https://doi.org/10.1371/journal.pone.0317054
Vancouver
Benedict K, Gold JAW, Toda M, Hsu J. Prevalence and features of allergic bronchopulmonary aspergillosis, United States, 2016–2022. PLOS ONE. 2025. doi:10.1371/journal.pone.0317054
BibTeX
@article{Benedict2025,
author = {Benedict, Kaitlin and Gold, Jeremy A W and Toda, Mitsuru and Hsu, Joy},
title = {Prevalence and features of allergic bronchopulmonary aspergillosis, United States, 2016–2022},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0317054}
}
EUVIMED